Stock APGE APOGEE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Apogee Therapeutics, Inc. Stock

Equities

APGE

US03770N1019

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
48.03 USD +4.32% Intraday chart for Apogee Therapeutics, Inc. -8.37% +71.90%
May. 15 Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases CI
May. 13 Apogee Therapeutics' Q1 Net Loss Widens MT

Financials (USD)

Sales 2024 * - Sales 2025 * - Capitalization 2.81B
Net income 2024 * -150M Net income 2025 * -201M EV / Sales 2024 * -
Net cash position 2024 * 273M Net cash position 2025 * 415M EV / Sales 2025 * -
P/E ratio 2024 *
-17.8 x
P/E ratio 2025 *
-14.8 x
Employees 91
Yield 2024 *
-
Yield 2025 *
-
Free-Float 61.38%
More Fundamentals * Assessed data

Chart Apogee Therapeutics, Inc.

Dynamic Chart

Latest news about Apogee Therapeutics, Inc.

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases CI
Apogee Therapeutics' Q1 Net Loss Widens MT
Apogee Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
BofA Securities Starts Coverage on Apogee Therapeutics With Buy Rating, $80 Price Target MT
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease and Other Inflammatory Diseases CI
Apogee Therapeutics, Inc.(NasdaqGM:APGE) added to S&P Biotechnology Select Industry Index CI
Apogee Closes $483 million Upsized Stock Offering MT
Apogee Therapeutics Prices Upsized $420 Million Share Offering MT
Sector Update: Health Care Stocks Advance Wednesday Afternoon MT
Apogee Therapeutics Shares Rise After Jefferies Raises Price Target MT
Jefferies Adjusts Price Target on Apogee Therapeutics to $75 From $37, Maintains Buy Rating MT
Apogee Therapeutics Unveils $350 Million Share Offering MT
Sector Update: Health Care Stocks Retreating Late Afternoon MT
Sector Update: Health Care Stocks Lower Tuesday Afternoon MT
Top Midday Gainers MT
More news

Analyst Recommendations on Apogee Therapeutics, Inc.

BofA Securities Starts Coverage on Apogee Therapeutics With Buy Rating, $80 Price Target MT
Jefferies Adjusts Price Target on Apogee Therapeutics to $75 From $37, Maintains Buy Rating MT
Wedbush Raises Apogee Therapeutics' PT to $87 From $40 After Reporting Initial Safety, PK Results From Phase 1 Trial of APG777; Maintains Outperform Rating MT
Guggenheim Adjusts Apogee Therapeutics' Price Target to $44 From $29, Maintains Buy Rating MT
BTIG Initiates Apogee Therapeutics With Buy Rating, Price Target is $43 MT
More recommendations

Press releases Apogee Therapeutics, Inc.

Apogee Therapeutics to Participate in Upcoming June Investor Conferences AQ
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases AQ
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results AQ
Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference AQ
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases AQ
More press releases

Quotes and Performance

1 day+4.32%
1 week-4.53%
Current month-4.51%
1 month+1.91%
3 months+37.62%
6 months+179.24%
Current year+71.90%
More quotes

Highs and lows

1 week
45.61
Extreme 45.6058
52.07
1 month
45.61
Extreme 45.6058
56.10
Current year
27.05
Extreme 27.05
72.29
1 year
14.19
Extreme 14.19
72.29
3 years
14.19
Extreme 14.19
72.29
5 years
14.19
Extreme 14.19
72.29
10 years
14.19
Extreme 14.19
72.29
More quotes

ETFs positioned on Apogee Therapeutics, Inc.

Name Weight AuM 1st Jan change Investor Rating
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 34 M€ +4.20% -
More ETFs positioned on Apogee Therapeutics, Inc.

Quotes

Date Price Change Volume
24-05-24 48.03 +4.32% 315,789
24-05-23 46.04 -3.82% 429,336
24-05-22 47.87 -2.72% 290,755
24-05-21 49.21 -6.12% 571,804

Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT

More quotes

Company Profile

Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD and COPD, respectively. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4Rα. Its earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, which are developed for the treatment of AD. APG990 is an SQ extended half-life mAb targeting OX40L for the treatment of AD. APG222 is one or more extended half-life SQ antibodies targeting both IL-13 and OX40L, which has the potential to improve outcomes in AD.
Sector
Biotechnology & Medical Research
Calendar
2024-06-04 - Annual General Meeting
Related indices
Russell 2000
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
48.03 USD
Average target price
84.83 USD
Spread / Average Target
+76.63%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
APOGEE THERAPEUTICS, INC. Stock Apogee Therapeutics, Inc.
+71.90% 2.81B
MODERNA, INC. Stock Moderna, Inc.
+67.53% 63.85B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.77% 41.83B
LONZA GROUP AG Stock Lonza Group AG
+44.98% 40.65B
CELLTRION, INC. Stock Celltrion, Inc.
-10.87% 27.12B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.30% 26.52B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.79% 18.69B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.70% 12.73B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.10% 12.11B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.41% 12.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. APGE Stock